All In MedTech

Device Trial Radar · NCT07428668

Change in IOP Fluctuation After DSLT

Change in Diurnal Intraocular Pressure Fluctuation Following Direct Selective Laser Trabeculoplasty

Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Apr 2, 2026

Primary completion

Apr 3, 2027

Study completion Apr 3, 2027

Sponsor

Lead sponsor
Ophthalmology Associates, Fort WorthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sengi
First posted
Feb 24, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single-center, single-arm, observational study designed to evaluate the change in diurnal intraocular pressure (IOP) fluctuation following Direct Selective Laser Trabeculoplasty (DSLT) in patients with primary open-angle glaucoma (POAG) who are on 1-3 IOP lowering medications. The study will be conducted at one site and will involve three key visits: a screening visit, a baseline/treatment visit, and a 6-month follow-up visit. During the screening visit, patients will undergo a comprehensive ophthalmic examination, and eligibility will be confirmed. The eye with the higher IOP will be selected if both eyes are eligible. At the baseline visit, diurnal IOP will be recorded at three time points (9am, 12pm, and 4pm) before DSLT is performed. The primary endpoint is the change in diurnal IOP fluctuation 6 months post-treatment. Secondary endpoints include changes in mean diurnal IOP and the proportion of eyes achieving a reduction in IOP fluctuations of ≥1 mmHg. Exploratory endpoints focus on demographic variables associated with IOP fluctuation changes.

Conditions

  • Glaucoma

Interventions

  • Voyager DSLTDevice

    Voyager DSLT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in diurnal intraocular pressure (IOP) fluctuationTime frame: Measured at baseline and at 6 months post-DSLT treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ophthalmology Associates

    Fort Worth, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.